Johnson & Johnson's IL-23 receptor-blocking oral peptide Icotyde, approved this spring, is emerging as a template for pill-form alternatives to antibody therapies.
The FDA approved icotrokinra (Icotyde) in March 2026 for adults and adolescents aged 12 and older with moderate-to-severe plaque psoriasis, making it the first oral peptide in this setting. The drug blocks the interleukin-23 receptor, a pathway previously addressed only by injectable biologics.
Approval rested on the Phase 3 ICONIC program of about 2,500 patients. Around 70% of participants reached clear or almost-clear skin and 55% achieved a 90% improvement in PASI score at week 16, with adverse event rates close to placebo through week 16 and no new safety signals through one year.
Dosing is 200 mg once daily on waking, at least 30 minutes before food, a reminder that oral peptides still require careful administration to survive digestion. Alongside enlicitide, icotrokinra is now frequently cited as evidence that oral peptide engineering has matured.
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.